Tag: Alnylam Pharmaceuticals
March 4, 2020
Market Stabilizes After Interest Rate Cut Amid Coronavirus Fears
The S&P 500 and the NASDAQ Composite Index were up nearly 2 percent, while the Dow Jones rose to 2.2... March 4, 2020
Vir and Alnylam Advance RNAi Therapeutics for COVID-19
Vir and Alnylam announced the development and commercialization of RNAi therapeutics targeting the virus that causes the disease COVID-19.
November 24, 2019
5 Top NASDAQ Biotech and Pharma Stocks: Fulcrum Climbs 73 Percent
Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
November 20, 2019
Alnylam Gets FDA Nod for Rare Disease Drug
The FDA's approval of Alnylam's Gilvaari treatment is the first approval of its kind for acute hepatic porphyria. August 13, 2019
Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ironwood Pharmaceuticals (NASDAQ:IRWD) has announced a US GI disease education and promotional agreement for Alnylam’s givosiran... January 21, 2019
Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel
Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an... October 15, 2018